Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

  1. Pivot, X.
  2. Pegram, M.
  3. Cortes, J.
  4. Lüftner, D.
  5. Lyman, G.H.
  6. Curigliano, G.
  7. Bondarenko, I.
  8. Yoon, Y.C.
  9. Kim, Y.
  10. Kim, C.
Revista:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Ano de publicación: 2019

Volume: 120

Páxinas: 1-9

Tipo: Artigo

DOI: 10.1016/J.EJCA.2019.07.015 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus